ImmuPharma PLC (LON:IMM) the specialist drug discovery and development company, has today announced the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.
Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.
A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.
Commenting on Tim McCarthy’s appointment, Dimitri Dimitrou, Chief Executive Officer, said: “We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim’s commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, Lupuzor(TM) , through its pivotal Phase III trial, as well as providing guidance on ImmuPharma’s long term business strategy.”